Pharmaceuticals

Peptide Based Metabolic Disorders Therapeutics Market Insights Report: Opportunities and Drivers 2030

February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the peptide based metabolic disorders therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Peptide Based Metabolic Disorders Therapeutics Market in 2026, and what figure is it projected to hit by 2030?

The market size for peptide based metabolic disorders therapeutics has expanded significantly in recent years. This market is projected to grow from $34.1 billion in 2025 to $39.05 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.5%. The historical growth of this market can be attributed to the rising prevalence of type 2 diabetes, the initial success of liraglutide and exenatide therapies, increasing clinical validation of peptide drugs, escalating obesity rates in developed economies, and a more comprehensive understanding of metabolic pathways.

The peptide based metabolic disorders therapeutics market size is anticipated to expand rapidly in the coming years. Its valuation is projected to reach $63.7 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.0%. The growth anticipated during this period can be attributed to the escalating global obesity burden, the increasing adoption of semaglutide and next-generation peptides, heightened investment in metabolic disorder drug pipelines, a growing need for long-term weight management solutions, and advancements in peptide drug delivery systems. Key trends in the forecast period encompass the rising adoption of GLP-1 receptor agonist therapies, an increasing focus on peptide-based obesity management, the expansion of long-acting injectable peptide formulations, the growing use of combination peptide therapies, and a rising demand for patient-friendly metabolic treatments.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16764&type=smp

Which Drivers Are Affecting Market Participation In The Peptide Based Metabolic Disorders Therapeutics Market?

The growing incidence of obesity is set to drive the expansion of the peptide-based metabolic disorders therapeutic market. Obesity is a medical condition marked by excessive body fat accumulation, which poses a significant health risk. The increasing cases of obesity stem from sedentary lifestyles, unhealthy dietary habits, genetic susceptibility, and environmental factors that promote calorie-dense diets and physical inactivity. Peptide-based metabolic disorders therapeutics are designed to manage conditions such as obesity by leveraging peptides to regulate metabolic functions, enhance insulin sensitivity, and control appetite, thereby improving patient health outcomes and mitigating the long-term health risks associated with these chronic conditions. For example, in December 2024, the Office for Health Improvement and Disparities, a UK-based government department, reported that the proportion of women recorded as living with obesity in early pregnancy increased from 25.4% during 2022 to 2023 to 26.2% from 2023 to 2024. This rising prevalence of obesity is therefore fueling the peptide-based metabolic disorder therapeutics market.

What Segment Categories Are Covered In The Peptide Based Metabolic Disorders Therapeutics Market?

The peptide based metabolic disorders therapeutics market covered in this report is segmented –

1) By Drug Type: Liraglutide, Exenatide, Other Drug Type

2) By Application: Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Other Applications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Liraglutide: Brand: Saxenda, Brand: Victoza, Generic Liraglutide, Liraglutide For Type 2 Diabetes, Liraglutide For Obesity

2) By Exenatide: Brand: Byetta, Brand: Bydureon, Exenatide For Type 2 Diabetes, Extended-Release Exenatide, Generic Exenatide

3) By Other Drug Type: Semaglutide, Dulaglutide, Albiglutide, Lixisenatide, GLP-1 Receptor Agonists, Pramlintide, Other Peptide-Based Drugs For Metabolic Disorders

Which Market Trends Are Opening Growth Opportunities In The Peptide Based Metabolic Disorders Therapeutics Market?

Leading companies in the peptide-based metabolic disorders therapeutics market are advancing innovative peptide-based treatments, including anti-diabetic biosimilars, to fulfill unmet medical requirements and expand patient care options. Peptide-based anti-diabetic biosimilars are therapeutic medications designed to emulate existing peptide-based diabetes therapies, providing comparable effectiveness and safety profiles to established drugs while potentially reducing treatment expenses through competitive pricing strategies. For instance, in January 2024, Glenmark Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Lirafit, a biosimilar version of the popular anti-diabetic drug Liraglutide in India. This medication is categorized as a glucagon-like peptide-1 receptor agonist (GLP-1 RA). This class of drugs replicates the function of the naturally occurring GLP-1 hormone, which is vital for regulating blood sugar levels. Clinical trials have demonstrated this biosimilar’s effectiveness in lowering glycemic parameters, supporting weight reduction, and improving cardiovascular safety. These represent critical advantages for managing diabetes and linked conditions such as obesity and cardiovascular diseases.

Which Major Firms Are Strengthening Their Position In The Peptide Based Metabolic Disorders Therapeutics Market?

Major companies operating in the peptide based metabolic disorders therapeutics market are Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Ipsen S.A., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Amgen Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Vertex Pharmaceuticals Incorporated, Amarin Corporation plc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/peptide-based-metabolic-disorders-therapeutics-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Peptide Based Metabolic Disorders Therapeutics Market?

North America was the largest region in the peptide based metabolic disorders therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide based metabolic disorders therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Peptide Based Metabolic Disorders Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16764&type=smp

Browse Through More Reports Similar to the Global Peptide Based Metabolic Disorders Therapeutics Market 2026, By The Business Research Company

Peptide Based Metabolic Disorders Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-based-metabolic-disorders-therapeutics-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Metabolic Disorders Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795